FDA cancer policy office
This article was originally published in The Gray Sheet
Executive Summary
Review of therapeutic biologics and drugs for oncology imaging will be consolidated by a new office within FDA's Center for Drug Evaluation & Research. The Office of Oncology Drug Products will engage in policy development, provide technical consultation to FDA's device center, and serve as a point of contact for cancer professional organizations, the National Cancer Institute and stakeholders, FDA announces July 16. Recruitment of a director will begin this summer; the reorganization wrap-up is slated for the first half of 2005...
You may also be interested in...
Oncology office seeks director
FDA is searching for a director of the newly formed Office of Oncology Drug Products. The agency is targeting candidates "outside as well as from inside the government," Acting Commissioner Lester Crawford states at an Aug. 2 National Press Club luncheon in Washington, D.C. Crawford called the job "appealing," and told the audience that the director would "be able to define this exciting new position." The new division will combine current review divisions for imaging agents, biologics and oncology drugs. The hire likely will coincide with a new, formal partnership with the National Cancer Institute (1"The Gray Sheet" July 19, 2004, In Brief)...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.